Loading...
XSHE300573
Market cap1.69bUSD
Jan 15, Last price  
70.80CNY
1D
-2.67%
1Q
-18.39%
Jan 2017
190.16%
IPO
1,112.33%
Name

Shenyang Xingqi Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300573 chart
P/E
51.69
P/S
8.45
EPS
1.37
Div Yield, %
1.43%
Shrs. gr., 5y
9.13%
Rev. gr., 5y
27.76%
Revenues
1.47b
+17.42%
190,537,300212,326,349218,631,429254,652,801287,439,466339,100,076360,006,690431,204,722542,434,237688,682,1251,027,914,8661,249,855,3701,467,569,910
Net income
240m
+13.39%
35,636,55943,703,17646,097,26531,010,18221,979,62254,279,32739,437,12113,658,66335,893,79687,978,613194,702,374211,684,305240,036,047
CFO
318m
+10.94%
24,539,17341,961,9188,398,46612,998,23721,432,75528,122,45532,697,21344,008,83774,081,244122,158,322306,955,942286,263,529317,568,222
Dividend
May 22, 20244.2 CNY/sh
Earnings
May 13, 2025

Profile

Shenyang Xingqi Pharmaceutical Co., Ltd engages in the research and development, production, and sale of ophthalmic products in China. It offers corneal, anti-bacteria, artificial tears, anti-inflammation, surgical perfusate, mydriactics, anti-fatigue, and pre dry and over dry eye treatment products. The company is based in Shenyang, China.
URL
http://www.sinqi.com
IPO date
Dec 08, 2016
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,467,570
17.42%
1,249,855
21.59%
Cost of revenue
818,885
922,267
Unusual Expense (Income)
NOPBT
648,685
327,588
NOPBT Margin
44.20%
26.21%
Operating Taxes
24,957
22,034
Tax Rate
3.85%
6.73%
NOPAT
623,728
305,554
Net income
240,036
13.39%
211,684
8.72%
Dividends
(177,110)
(79,284)
Dividend yield
0.78%
0.72%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
70,058
7,116
Long-term debt
4,448
13,387
Deferred revenue
71,581
71,496
Other long-term liabilities
1
Net debt
(418,913)
(506,455)
Cash flow
Cash from operating activities
317,568
286,264
CAPEX
(261,963)
Cash from investing activities
(261,942)
Cash from financing activities
(84,168)
FCF
418,463
89,251
Balance
Cash
480,418
515,450
Long term investments
13,001
11,508
Excess cash
420,040
464,464
Stockholders' equity
738,973
774,240
Invested Capital
1,413,744
1,164,234
ROIC
48.39%
29.82%
ROCE
35.37%
20.11%
EV
Common stock shares outstanding
124,371
123,977
Price
182.32
104.07%
89.34
-8.57%
Market cap
22,675,322
104.72%
11,076,116
-8.09%
EV
22,256,409
10,569,661
EBITDA
739,745
401,963
EV/EBITDA
30.09
26.30
Interest
1,888
937
Interest/NOPBT
0.29%
0.29%